| Realtime | Geld | Brief | Zeit | 
|---|---|---|---|
| 26,840 | 27,160 | 08:36 | |
| 26,800 | 27,200 | 08:30 | 
| Stück | Geld | Kurs | Brief | Stück | 
|---|---|---|---|---|
| 27,340 | 1.000 | |||
| Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/gxe.htm [/URL] | ||||
| 1.000 | 26,960 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.000 | 1,000 | 1.000 | ||
| Uhrzeit | Aktienkurs | Stück | 
|---|---|---|
| 14:31:16 | 26,860 | 118 | 
| 14:31:16 | 26,820 | 1 | 
| 14:31:16 | 26,820 | 200 | 
| 14:31:16 | 26,820 | 117 | 
| Tagesumsatz Xetra | - | 0 | 
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Galapagos NV: Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development | 283 | GlobeNewswire (Europe) | New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board
			Mechelen, Belgium; October 30, 2025, 21:01 CET - Galapagos NV (Euronext & NASDAQ:... ► Artikel lesen | |
| 24.10. | GALAPAGOS NV - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 23.10. | Galapagos NV: Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors | 368 | GlobeNewswire (Europe) | Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667... ► Artikel lesen | |
| 22.10. | Galapagos stock price target raised to $28 from $27 at RBC Capital | 1 | Investing.com | ||
| GALAPAGOS NV Aktie jetzt für 0€ handeln | |||||
| 22.10. | Galapagos: RBC Kapital erhöht Kursziel auf 28 US-Dollar | 1 | Investing.com Deutsch | 
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | Bioxyne Limited: Q1-Aktivitätenbericht 30. September 2025 | IR-WORLD | Höhepunkte
 
 
   
 
 
  -          Rekordquartalsumsatz von 14,1 Millionen $, ein Anstieg um 210 % gegenüber Q1 GJ25 und ein Anstieg um 47 % gegenüber Q4 GJ25.
 
 
  -          Erhebliche... ► Artikel lesen | |
| Do | Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 | GlobeNewswire (Europe) | IND application filed for MP0712, the Company's lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images... ► Artikel lesen | |
| Do | Hemostemix Inc.: Hemostemix's Boots on the Ground in Florida October Update | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 02:02 | Onco-Innovations Limited: Onco-Innovations Appoints Jared Rushton to Board of Directors | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company"),is pleased to announce the appointment of... ► Artikel lesen | |
| Do | QIAGEN N.V.: QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025 | Business Wire | New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA  		   Workflow on EZ2 Connect Fx delivers high-quality... ► Artikel lesen |